|
業務類別
|
Biotechnology |
|
業務概覽
|
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease. |
| 公司地址
| 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453 |
| 電話號碼
| +1 617 651-5940 |
| 傳真號碼
| +1 512 872-5121 |
| 公司網頁
| https://www.spyre.com |
| 員工數量
| 102 |
| Dr. Cameron Turtle, D.Phil. |
Director, President and Chief Executive Officer |
美元 665.00K |
10/04/2026 |
| Ms. Heidy King-Jones |
Chief Legal Officer and Corporate Secretary |
美元 490.00K |
10/04/2026 |
| Dr. Scott L. Burrows, M.D. |
Chief Financial Officer and Principal Accounting Officer |
美元 490.00K |
10/04/2026 |
| Mr. Sheldon Sloan |
Chief Medical Officer |
美元 503.00K |
10/04/2026 |
|
|
| Mr. Jeffrey W. Albers, J.D.,M.B.A. |
Chairman of the Board |
10/04/2026 |
| Ms. Laurie D. Stelzer, M.B.A. |
Independent Director |
10/04/2026 |
| Mr. Mark C. McKenna |
Independent Director |
10/04/2026 |
| Dr. Cameron Turtle, D.Phil. |
Director, President and Chief Executive Officer |
10/04/2026 |
| Dr. Michael Henderson, M.D. |
Independent Director |
10/04/2026 |
| Mr. Tomas Kiselak |
Independent Director |
10/04/2026 |
| Dr. Sandra Milligan, J.D.,M.D. |
Independent Director |
10/04/2026 |
|
|
|
|
